Publication | Closed Access
SGLT 2 inhibitor, Canagliflozin attenuates myocardial infarction in the diabetic and non-diabetic heart
26
Citations
0
References
2018
Year
Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseNon-diabetic HeartAtherosclerosisDiabetesPharmacologyCardiovascular PharmacologySglt 2PharmacotherapyMedicineCardiologyAcute Myocardial InfarctionMyocardial Infarction
No additional data available for this publication yet. Check back later!